Literature DB >> 15154001

Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.

Lina M Lopez, Adel A Wassef, Melissa S Molloy, Nina G Williams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154001     DOI: 10.1038/sj.npp.1300461

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  5 in total

Review 1.  The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.

Authors:  Dennis R Grayson; Alessandro Guidotti
Journal:  Neuropsychopharmacology       Date:  2012-09-05       Impact factor: 7.853

2.  Functional hallucinations in schizophrenia responding to adjunctive sodium valproate.

Authors:  Ravi Philip Rajkumar
Journal:  Indian J Psychol Med       Date:  2012-01

Review 3.  The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.

Authors:  Ralf Brisch; Arthur Saniotis; Rainer Wolf; Hendrik Bielau; Hans-Gert Bernstein; Johann Steiner; Bernhard Bogerts; Katharina Braun; Anna Katharina Braun; Zbigniew Jankowski; Jaliya Kumaratilake; Jaliya Kumaritlake; Maciej Henneberg; Tomasz Gos
Journal:  Front Psychiatry       Date:  2014-05-19       Impact factor: 4.157

4.  Reduced crowding and poor contour detection in schizophrenia are consistent with weak surround inhibition.

Authors:  Valentina Robol; Marc S Tibber; Elaine J Anderson; Tracy Bobin; Patricia Carlin; Sukhwinder S Shergill; Steven C Dakin
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

Review 5.  Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study.

Authors:  Ping-Tao Tseng; Yen-Wen Chen; Weilun Chung; Kun-Yu Tu; Hung-Yu Wang; Ching-Kuan Wu; Pao-Yen Lin
Journal:  Medicine (Baltimore)       Date:  2016-01       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.